More specifically, in younger patients with the MCD and N1 genetic subtypes of non-GCB DLBCL, the addition of ibrutinib to R-CHOP resulted in remarkable 100% three-year EFS and OS rates, a substantial improvement compared to R-CHOP alone (MCD: 48% EFS, 69.6% OS; N1: 50% EFS and OS) [130]. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.